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Abstract
Background: Advanced pelvic radiotherapy techniques aim to reduce late bowel toxicity which can severely
impact the lives of pelvic cancer survivors. Although advanced techniques have been largely adopted worldwide, to
achieve their aim, knowledge of which dose-volume parameters of which components of bowel predict late bowel
toxicity is crucial to make best use of these techniques.
The rectum is an extensively studied organ at risk (OAR), and dose-volume predictors of late toxicity for the rectum
are established. However, for other components of bowel, there is a significant paucity of knowledge. The
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) reviews recommend dose-volume
constraints for acute bowel toxicity for peritoneal cavity and bowel loops, although no constraints are
recommended for late toxicity, despite its relevance to our increasing number of survivors. This systematic review
aims to examine the published literature to seek dose-volume predictors and constraints of late bowel toxicity for
OARs (apart from the rectum) for use in clinical practice.
Methods: A systematic literature search was performed using Medline, Embase, Cochrane Library, Web of Science,
Cinahl and Pubmed. Studies were screened and included according to specific pre-defined criteria. Included studies
were assessed for quality against QUANTEC-defined assessment criteria.
Results: 101 studies were screened to find 30 relevant studies. Eight studies related to whole bowel, 11 to small
bowel, and 21 to large bowel (including 16 of the anal canal). The anal canal is an important OAR for the
development of late toxicity, and we recommend an anal canal Dmean <40Gy as a constraint to reduce late
incontinence. For other components of bowel (sigmoid, large bowel, intestinal cavity, bowel loops), although
individual studies found statistically significant parameters and constraints these findings were not corroborated in
other studies.
Conclusions: The anal canal is an important OAR for the development of late bowel toxicity symptoms. Further
validation of the constraints found for other components of bowel is needed. Studies that were more conclusive
included those with patient-reported data, where individual symptom scores were assessed rather than an overall
score, and those that followed statistical and endpoint criteria as defined by QUANTEC.
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Background
Pelvic radiotherapy is used to treat approximately 17,000
patients per year in the UK with urological, gynaeco-
logical and colorectal malignancies [1]. For a significant
proportion of these patients, pelvic radiotherapy im-
proves survival outcomes. For others, it reduces the risk
of pelvic recurrences, which can both cause distressing
symptoms and be difficult to manage.
Although contributing to the cure of many pelvic can-
cer survivors, pelvic radiotherapy is associated with late
toxicity, in particular late bowel toxicity. Serious
life-threatening toxicity such as bowel obstruction, fistu-
lae and bleeding requiring transfusion occur in 4–10% of
patients 5–10 years after treatment [2]. Furthermore, an
important consideration for the growing number of sur-
vivors of pelvic cancers is that 50% of patients report late
bowel toxicity symptoms which adversely affect their
quality of life after pelvic radiotherapy.
Late bowel toxicity is generally attributed to radiation
to bowel and rectum and these are considered the or-
gans at risk (OARs). Advanced radiotherapy techniques
for pelvic treatments are continually evolving, with the
aim of reducing dose to these OARs.
However, to determine whether the dose reductions
achieved by these techniques are likely to translate into
reduced toxicity for patients requires detailed knowledge
of the dose-volume parameters and constraints for these
OARs. Once dose-volume constraints are known these
can be used to limit the risk of toxicity and potentially
allow safe dose escalation with modern delivery
techniques.
In 2010 the Quantitative Analysis of Normal Tissue
Effects in the Clinic (QUANTEC) review summarised
the available dose-volume data for bowel toxicity, with
one review focussing on rectum and the other on stom-
ach and bowel. For rectum, an extensively studied OAR,
QUANTEC reviewed a large amount of high-quality
data and dose-volume constraints for rectum for acute
and late toxicity were recommended [3]. These are com-
monly incorporated into radiotherapy protocols in clin-
ical practice.
However, for bowel there was a relative paucity of
data. QUANTEC reviewed data from six papers which
examined the dose-volume relationship of bowel with
acute bowel toxicity only [4]. For late bowel toxicity,
there was no detailed dose-volume relationship analysis
described. Studies mentioned were trial data detailing
the incidence of late bowel toxicity at the
dose-fractionations used within each trial, though no
specific dose-volume predictors can be derived from this
information.
The QUANTEC reviewers suggest that the constraints
identified for acute bowel toxicity may be applied for late
bowel toxicity however clarify that “this correlation is
not established”. Further, although QUANTEC examined
the peritoneal cavity and small bowel loops as OARs,
the potential of other bowel components as OARs for
bowel toxicity such as sigmoid, duodenum, ileum and
anal canal are not detailed.
In a separate paper by Jackson et al., QUANTEC [5]
highlighted issues which hinder the development of
dose-volume constraints and the pooling of results from
different studies, including variations in toxicity end-
point definition, statistical standards, and anatomical
definitions of OARs. They recommended several criteria
to assess the quality of future dose-volume studies and
to facilitate meta-analysis of these studies.
With reduction of late bowel toxicity being a prime
aim of advanced pelvic radiotherapy techniques, the lack
of clear dose-volume constraints in this setting has been
acknowledged and more studies have been reported.
This study aims to systematically review published stud-
ies examining the dose-volume predictors of all compo-
nents of bowel (excluding rectum) for late bowel
toxicity, including a quality assessment of these studies
from criteria derived from QUANTEC.
From this review we aim to determine the clinically
useful dose-volume constraints for late bowel toxicity
which can guide protocols for advanced pelvic radiother-
apy techniques.
Methods
Information sources and search strategy
A systematic search was carried out using Medline, Pre-
medline, Embase, Pubmed and Web of Science on 15th
October 2013; Updated searches were performed on
10th November 2014, 3rd September 2015 and 1st May
2017 to ensure all new literature was included. The-
saurus and natural language terms around the concepts
of “radiotherapy, radiotherapy injuries, side effects, tox-
icity, intestines bowel, dose, dose fractionation, dose re-
sponse relationship” were identified for each database.
Duplicate references were removed.
Study selection
Eligible studies were English language studies, involving
human adult patients treated for any gastrointestinal,
urological or gynaecological malignancies with external
beam radiotherapy. Studies correlating the dose-volume
relationship of any component of bowel from duodenum
to anal canal with late bowel toxicity were included,
apart from those focussed on the rectum, given that it
has already been extensively studied as an OAR. Late
toxicity was defined as more than 3 months from com-
pletion of radiotherapy.
Excluded studies were review articles and letters, stud-
ies involving brachytherapy only, or stereotactic body
radiotherapy. Both full text papers and conference
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abstracts were considered, however studies with insuffi-
cient methodological detail to be able to repeat the
method on an independent sample of patients were
excluded.
All abstracts were independently screened by two re-
viewers (RJ, EH) for inclusion. Full papers of abstracts
were acquired and further assessed for eligibility, with
any discrepancies discussed between the two reviewers.
The reference lists of all the included papers were
hand-searched for additional references.
Data extraction and synthesis of results
Bowel can be defined in several different ways and for
the purpose of this review studies were divided into
those looking at the whole bowel (including bowel loops
and peritoneal cavity), small bowel (and its components)
and large bowel (and its components). For each included
study the number of patients, proportion with the tox-
icity, tumour site, OAR studied, toxicity definition, treat-
ment details and key findings were tabulated.
Furthermore, the recommendations from QUANTEC
[5] on quality of dose-volume studies were reviewed, and
those criteria that can be applied to this subject were se-
lected (see Table 1). Each included study was assessed for
quality against these statistical and endpoint criteria.
Results
Outcomes of the systematic search are shown in Fig. 1.
Overall, 30 studies involving a total of 5126 patients
were included as detailed in Table 2. Twenty-one studies
included patients with prostate cancer, 6 with gynaeco-
logical cancers (cervical and endometrial), and 2 each in-
cluded bladder and pancreatic cancers. Most studies (n
= 18) included less than 100 patients, with 9 studies hav-
ing less than 50 patients included.
Table 3 details studies for whole and small bowel, and
Table 4 those for large bowel. In each table the final two
columns indicate the quality assessment criteria of statis-
tical and endpoint considerations as defined in Table 1.
If a specific criterion is met its number is noted in the
column.
Whole bowel
Eight papers (including 445 patients) examined the
dose-volume relationship of whole bowel either using bowel
loops or intestinal/peritoneal cavity as detailed in Table 3.
Peritoneal cavity
Late bowel toxicity was associated with low doses to the
peritoneal cavity (V10–30Gy) in 2 studies.
Mouttett-Audouard et al. [6] found, in 37 cervical cancer
patients, an association between “bigger volumes” of
bowel receiving 10–30Gy and grade 1–3 Common Ter-
minology Criteria Adverse Events (CTCAE) toxicity, al-
though specific cut-offs were not reported. Deville et al.
[7] found that peritoneal cavity volume and V20 were
both associated with grade 1 Radiation Therapy Oncol-
ogy Group (RTOG) toxicity. Again no constraints were
derived.
Bowel loops
Two studies [8, 9] investigated bowel loops as an OAR
for late toxicity, both with an identical definition of
bowel loops. Guerrero-Urbano et al., in 79 patients who
had their prostate and pelvic nodes treated, found V40,
V45 and V60 bowel loops to be predictive of late grade
2 RTOG-graded diarrhoea. They suggested constraints
of V40 < 124 cc, V45 < 71 cc and V60 < 0.5 cc to reduce
grade 2 RTOG toxicity, although no complication rates
associated with these constraints are detailed. McDonald
et al. in their study of 47 bladder cancer patients sug-
gested constraints to reduce the risk of grade ≥ 2 RTOG
toxicity to less than 25% (V30 < 178 cc; V40 < 151 cc;
V45 < 139 cc; V60 < 98 cc and V65 < 40 cc), although it
must be noted that only 3 patients within this study had
grade 2 toxicity.
Small bowel and its components
Eleven studies (including 1401 patients) were included
in this section, with 6 studies examining small bowel
Table 1 Statistical and Endpoint Considerations from QUANTEC
[5]
Statistical considerations
1 Basic statistical data provided on incidence of toxicity
-Both number of subjects and number of events should be reported
-If an estimate of incidence is given the standard error should be
supplied
2 Numerical labeling of response histogram – if into groups eg. quartiles
must state number of patients in each quartile
3 When predictive models are correlated with complications parameter
estimates must be stated with their standard error
4 Complication rates associated with constraints must be reported
5 “Goodness of fit” to be reported such as Chi-squared
6 Discriminator statistics reported such as receiver operating
characteristic curves
7 Full organ volumes (rather than partial) should be used
-If this is not possible absolute volumes should be used or a standard
method of normalization
-A clear statement of organ volume definition should be given
Toxicity Endpoint considerations
1 Symptom-specific information rather than a portmanteau endpoint
(eg. RTOG gr 2) should be used
2 Consideration that symptoms may be attributed to pre-radiotherapy
co-morbidities
3 Patient-reporting of symptoms may be important
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and 4 examining the duodenum, as detailed in Table 3.
No papers investigating the ileum or jejunum were
found.
Small bowel
2 of 6 studies found positive correlations with late bowel
toxicities and small bowel volume parameters in cervical
cancer patients. However, the positive parameters were
different between the studies, with Isohashi et al. [10]
recommending a V40 < 340 cc, and Chopra et al. [11]
recommending a V15 < 275 cc. Lind et al. [12] found that
a mean small bowel dose >50Gy was of significance,
however could not clarify whether toxicity was linked
specifically to small bowel, sigmoid or anal sphincter
dose, making these results difficult to interpret.
Duodenum
3 of 4 studies found positive correlations between
dose-volume parameters and duodenal toxicity. Two
studies found V55 to be an important predictor, though
with differing constraints. Kelly et al., in 106 pancreatic
patients recommending a V55 < 1 cc [13] and Verma et
al. in 105 gynaecological patients recommending a V55
< 15 cc [14]. Huang et al. [15] found V25 to be the sig-
nificant predictor for pancreatic cancer patients treated
with concurrent gemcitabine; with a V25 < 45% toxicity
rates were 8%, above this constraint toxicity was 48%.
Investigation of individual duodenal segments did not
reveal any positive findings [16].
Large bowel and its components
21 studies (including 5006 patients) were included in
this section (see Table 4), with 2 examining large bowel,
3 examining sigmoid and 16 studies examining the anal
canal/sphincter region.
Large bowel and sigmoid Colon
Chopra et al. [11] found on multivariate analysis that
V15 of large bowel was associated with grade 3 CTCAE
toxicity (p < 0.03), and recommended with the use of the
2 additional studies 
included from 
references
30 studies included in 
review
5740 records screened
5639 records excluded
101 full text articles 
assessed for eligibility
73 full texts excluded: 
Acute toxicity: 17
No relation to DV 
parameters: 31
Planning study: 4
SBRT: 5
Rectal study: 5
Review: 5
Other: 6
28 papers included from 
searches
11287 records identified 
through database 
searching
5547 duplicates 
removed
Fig. 1 Systematic Search Outcomes
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Table 2 All included studies
Author Year Cancer site No
of
pts
Pts with tox OAR studied Toxicity score
used
RT Type Primary RT
Dose (Gy/#)
Pelvic RT
dose (Gy/
#)
Concurrent
chemo use
Adkison
[34]
2012 Prostate 53 20 small bowel CTCAE v3.0 IMRT 70/28 56/28 no
al-Abany
[18]
2005 Prostate 65 9 anal
sphincter
region
Own
questionnaire
3D 70.2/39 NS no
Alsadius
[19]
2012 Prostate or
prostatic bed
403 51 anal
sphincter
region
Own
questionnaire
3D 70/35 NS no
Buettner
[20]
2012 Prostate 388 57 anal canal Common
grading scheme
3D 64/32 or 74/37 NS no
Chopra [11] 2014 Cervix (post-
op)
71 9 small bowel,
large bowel
CTCAE v3.0 IG-MRT (46);
3D (25)
50/25 50/25 63/71
cisplatin
Deville [31] 2010 Prostate 30 2 intestinal
cavity
RTOG IMRT 79.2/44 45/25 no
Deville [7] 2012 Prostatic bed 36 5 intestinal
cavity
RTOG IMRT 70.2/39 45/25 no
Ebert [35] 2015 Prostate 754 Symptom
specific
Anal canal LENT-SOMA IMRT 66–78/33–38 NS no
Fokdal [14] 2005 Prostate or
bladder
71 Symptom
specific
small bowel LENT-SOMA Conformal 60/30 (bladder)
69.6/35
(prostate)
48-60Gy
bladder;
NS for
prostate)
no
Fonteyne
[17]
2007 Prostate 241 Symptom
specific
small bowel,
sigmoid
RTOG and
“RILIT”
IMRT 74/37–80/40 NS no
Green [36] 2015 Prostate or
prostatic bed
73 10 Intestinal
cavity
CTCAE v4.0 IMRT/VMAT 61–79.2 45 no
Guerrero-
Urbano [8]
2010 Prostate &
Pelvic nodes
79 21 bowel loops RTOG diarrhoea
& LENT SOMA
diarrhoea
IMRT 70/35 50/35 or
55/35
no
Huang [15] 2011 Pancreas 46 8 duodenum CTCAE v4.0 3D or IMRT 42/15 42/15; 36/
15; 38/19
Gemcitabine;
18 pts.
erlotinib in
addition
Isohashi
[10]
2013 Cervix (post-
op)
97 16 peritoneal
cavity, small
and large
bowel
RTOG/EORTC 2D or 3D 50/25 50/25 All
nedaplatin
Kelly [13] 2013 Pancreas 106 20 duodenum CTCAE v4.0 3D or IMRT 50.4/28 (78pts);
57.5–75.4 in
28–39# (28pts)
50.4/28
(78pts);
57.5–75.4
in 28–39#
(28pts)
Gemcitabine
5-FUor
capecitabine
+/−
cetuximab or
erlotinib
Author Year Cancer site No
of
pts
Pts with tox OAR studied Toxicity score
used
RT Type RT Dose (Gy/#) Pelvic RT
dose (Gy/
#)
Concurrent
chemo use
Koper [25] 2004 Prostate 266 141 anal canal RTOG
(simplified)
Symptom
questionnaire
3D or 2D 66/33 NS no
Lind [12] 2016 Cervical or
Endometrium
519 63 Anal
sphincter,
small bowel,
sigmoid
Own
questionnaire
(defecation into
clothing
without
forewarning)
2D or 3D 40–46
(endometrium)
or 55–70
(cervix)
NS Not stated
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constraints-V15 < 250 cc, V30 < 100 cc and V40 < 90 cc
grade 3 toxicity could reduce from 26.7 to 5.4%.
For the sigmoid colon Fonteyne et al. [17] found in
241 prostate patients that sigmoid V40 was associated
with grade 1 diarrhoea and blood loss; they recom-
mended V40 < 10% and V30 < 16% to avoid grade 1–2
diarrhoea. Mouttet-Aldouard et al. [6] also found sig-
moid V30–40Gy to be significantly correlated (p < 0.006)
with “digestive toxicity” although no specific cut-offs
were defined.
Anal canal
15 of 16 studies had positive findings relating
dose-volume parameters and Normal Tissue Complica-
tion Probability (NTCP) models of the anal canal/
sphincter to late toxicity. Most defined the anal canal as
the distal 3 cm of rectum.
Dmean
5 studies [18–22] found Dmean anal canal or anal
sphincter region to be most predictive of toxicity, 4 of
Table 2 All included studies (Continued)
Mavroidis
[27]
2005 Prostate 65 Symptom
specific
anal
sphincter
Own
questionnaire
3D 70.2/39 NS no
Mcdonald
[9]
2015 Bladder 47 10 bowel loops RTOG 3D 64/32 64/32 21 received
5-FU/MMC
Mouttet-
Audouard
[6]
2015 Cervical 37 8 Small bowel
[defined as
peritoneal
cavity],
sigmoid
CTCAE v4.0 IMRT
(tomotherapy)
60/28 50/28 Cisplatin
Peeters [21] 2006 Prostate 641 146 Anal wall RTOG/EORTC
plus 5 specified
symptoms
3D (41 pts.
had IMRT
boost)
68/34 or 78/39 NS no
Peeters [28] 2006 Prostate 368 32 Anal wall Incontinence
(no specific
questionnaire)
3D (22 pts.
had boost)
68/34 or 78/39 NS no
Poorvu [16] 2013 Cervix or
Endometrium
(+ PA nodes)
46 3 peritoneal
cavity, small
bowel,
duodenal
segments
CTCAE v4.0 IMRT 45/25 (22pts);
PAN boost 50–
65 (33pts)
45/25 &
PAN boost
50–65 (33
pts)
24 received
cisplatin
Smeenk
[26]
2012 Prostate 48 21 Anal
sphincter
muscles
Presence of
frequency,
urgency and
incontinence
3D (n = 43,
IMRT (n = 5)
67.5/27 or 70/
28
NS no
Smeenk
[22]
2012 Prostate 36 23 Anal wall Late RILIT score:
urgency,
incontinence,
frequency
3D 67.5/27 or 70/
28
NS no
Taussky [37] 2003 Prostate 73 unclear anal canal UCLA, FACT-P
and EORTC
QLQ-PR25
3D 66.6–72/ 37–40 NS no
Thor [29] 2015 Prostate 212 Symptom
specific
Anal
sphincter
Own
questionnaire
with 19
descriptors for 4
symptoms
3D 70-78Gy NS no
Verma [30] 2014 Cervix &
Endometrium
105 9 duodenum RTOG and
endoscopic
findings
IMRT 45–50 (60-66Gy
boost)
45–50
(60–66
boost)
58 pts.
platinum
agents
Vordermark
[23]
2003 Prostate or
prostatic bed
44 14% severe
incontinence
anal canal 10 question
continence
questionnaire
3D 58–72/29–36 NS No
Yeoh [24] 2016 Prostate 106 72% Anal wall LENT-SOMA
total score
3D 66–74.4/ 33–4 NS no
Abbreviations: Pts Patients, OAR Organs at risk, RT Radiotherapy, Gy Gray, # Fraction, NS Not stated, CTCAE Common terminology criteria for adverse events, RTOG
Radiation therapy oncology group, LENT-SOMA Late Effects of Normal Tissue – Subjective Objective Management Analytical, RILIT Radiation induced late intestinal
toxicity, EORTC European Organisation for Research and Treatment of Cancer, IG-IMRT Image-guided intensity modulated radiotherapy, IMRT Intensity modulated
radiotherapy, VMAT Volumetric modulated arc therapy, PA nodes Para-aortic nodes, pts Patients
Jadon et al. Radiation Oncology           (2019) 14:57 Page 6 of 14
Table 3 Whole bowel and small bowel studies – significant findings and quality assessment
Quality Assessment
Author OAR studied OAR defined Toxicity definition Pts with
toxicity
Significant findings Statistical
criteria
met (1–7)
Endpoint
criteria
met (1–3)
Deville [7] Intestinal cavity Intestinal cavity below L4–5 RTOG Gr≥ 1 5/36
(14%)
Toxicity associated with
total volume & V20. No
constraints specified.
1,7
(n/a: 2–6)
None
Mouttet-
Audouard
[6]
“Small bowel”
[outlined as
abdominal
cavity hence
included in
this section]
Entire abdominal cavity
including all possible organ
locations to iliac crests or
D12/L1
CTCAE v4.0 Gr1–3 –
diarrhoea or “whole
digestive toxicity”
(diarrhoea, gastritis,
bleeding, pain,
incontinence)
8/37
(21.6%)
17/37
(46%)
Larger volumes of bowel
receiving 10–30Gy
associated with diarrhoea &
whole digestive toxicity. (No
constraints specified)
“Whole digestive toxicity”
associated with many
parameters including D20%-
D95%.
1, 7
(n/a 2–6)
2
Green [36] Intestinal cavity Not stated CTCAE v4.0 9 (12%) No dose-volume relation-
ship found.
1 (n/a 2–
6)
2
Deville
[31]
Intestinal cavity Large & small bowel below
L4–5
RTOG Gr≥ 2 2/30 (6%) No dose-volume relation-
ship found
1,7
(n/a 2–6)
None
Isohashi
[10]
Peritoneal
cavity
Volume surrounding small
bowel loops to edge of
peritoneum excluding
bladder & rectum
RTOG/EORTC Gr≥ 2 16/97
(16.5%)
No dose-volume relation-
ship found
1,7
(n/a 2–6)
2
Poorvu
[16]
1. Peritoneum
2. Peritoneum
+ Colon
1. Possible location of small
bowel excluding solid organs
& retroperitoneal structures.
2. Peritoneum (as above) plus
asc & desc colon
CTCAE v4.0 Gr > 3 3/46
(6.5%)
No dose-volume relation-
ship found
1, 7
(n/a 2–6)
2
Guerrero-
Urbano [8]
Bowel loops Loops from recto-sigmoid
junction to 2 cm above PTV
RTOG Gr≥ 2
diarrhoea; LENT-
SOMA consistency &
frequency- worst
grade
21/79
(26%)
RTOG
diarrhoea;
≥gr2 6/79
(7.6%)
V40, V45, V60 and bowel
volume of > 450 cc had
both higher RTOG &
LENTSOMA diarrhoea.
Constraints suggested: V40
< 124 cc, V45 < 71 cc, V60 <
0.5 cc for RTOG<gr 2
1,7
(n/a 2–3)
1
McDonald
[9]
Bowel loops Loops from recto-sigmoid
junction to 2 cm above PTV
RTOG Gr≥ 1 7/47
(14.9%)
gr1; 3/47
(6.4%) gr2
Constraints for < 25%≥ gr2
toxicity: V30 < 178 cc;V35 <
163 cc;V40 < 151 cc;V45 <
139c; V50 < 127 cc; V55 <
115 cc; V60 < 98 cc V65 < 40
cc
1,4,7
(n/a 2–3)
2
Chopra
[11]
Small bowel 2 cm above target, individual
small bowel loops (unclear
how differentiated from large
bowel)
CTCAE v3.0 Gr3+ 9/71
(12.6%)
V15 associated with ≥gr3
toxicity. Recommend V15 <
275 cc, V30 < 190 cc, V40 <
150 cc reduces Gr3 toxicity
from 23.6 to 5.6%.
1, 4, 6
(n/a 2,3)
2
Isohashi
[10]
Small bowel Bowel loops remaining after
exclusion of large bowel
loops
RTOG/EORTC Gr≥ 2 16/97
(16.5%)
V40 best predictor of late
toxicity; Recommend V40 <
340ml to reduce toxicity
from 46.2 to 8.7%
1,4,6,7
(n/a 2,3)
2
Lind [12] Small bowel All visible small bowel in
small pelvic cavity to caudal
part of sacroiliac joints
Defecation into
clothing without
warning > 1 in last 6
months
63/519
(12.1%)
Mean dose>50Gy to small
bowel or sigmoid or anal
sphincter region associated
with symptom (findings for
individual organs not
clarified)
1, 7 (n/a
2,3)
1,2,3
Adkison
[34]
Small bowel Not clearly defined CTCAE v3.0 Gr1 and
Gr2
Gr1 16/53
(30%); Gr2
4/53 (8%)
No dose-volume relation-
ship with V30-V60 small
bowel
1
(n/a 2–6)
None
Fokdal [14] Small bowel Opacified & unopacified small
intestine loops (outer contour
LENT-SOMA G1–4 Symptom
specific
No dose-volume relation-
ship found
1,7
(n/a 2–6)
1,2,3
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faecal incontinence and 1 of faecal urgency, as sum-
marised in Table 5. There was relative consistency in the
recommended Dmean constraints between 40-47Gy,
despite the OARs being defined slightly differently.
Other dose volume histogram (DVH) and dose-surface
histogram (DSH) parameters
Many other DVH parameters of the anal canal were
found to be important, including Dmin [23], Dmax,
Dmedian [14], V40 [24], V65 [21] and V90% dose [25];
these were all in individual findings with little corrobor-
ation between studies. Vordermark et al. also found that
the treatment field border was important, with those
with a lower border 2 mm below ischial tuberosities
more likely to have severe incontinence compared with
5 mm above the ischial tuberosities.
Buettner et al. [20] also examined incontinence
using dose surface maps (DSM) for the anal canal.
They found the mean dose to the anal surface and
the lateral extent of the DSM to be most correlated
with subjective sphincter toxicity. They recommend
45Gy for surface-based mean-dose to the anal canal
to reduce toxicity.
Anal sphincter muscles
Smeenk et al. [26] related dose to individual sphincter
muscles to urgency, frequency and incontinence. To re-
duce urgency and incontinence to below 5% they recom-
mended a mean dose <30Gy to internal anal sphincter,
<10Gy to the external sphincter, < 50Gy to puborectalis
and < 40Gy to the levator ani muscles.
Normal tissue complication probability (NTCP) modeling
Four studies detailed NTCP models for the anal canal
[20, 27–29], three of fitting data to a
Lyman-Kutcher-Burman (LKB) model. Buettner et al.
identified mean-dose anal canal parameters related to
grade 2 RTOG toxicity, and Peeters et al. looked at anal
wall parameters in relation to faecal incontinence, as de-
tailed in Table 4. Peeters et al. further modified their
model to incorporate a previous history of abdominal
surgery and found this improved the model fit, suggest-
ing a decreased radiation tolerance for patients with this
risk factor. Thor et al. [29] proposed LKB models for
pain, mucus and faecal leakage, although their findings
are difficult to use practically as within their study they
use data from two different centres, where each toxicity
is defined differently between centres. Mavroidis et al.
Table 3 Whole bowel and small bowel studies – significant findings and quality assessment (Continued)
Quality Assessment
Author OAR studied OAR defined Toxicity definition Pts with
toxicity
Significant findings Statistical
criteria
met (1–7)
Endpoint
criteria
met (1–3)
& contents) from 1st slice to
minor pelvis
Fonteyne
[17]
Small bowel Not clearly defined RTOG and “RILIT” Gr1
& Gr2
Gr1 112/
241 (46%),
Gr2 32/
241(13%)
No dose-volume relation-
ship found
1,
(n/a 2–6)
1,2
Poorvu
[16]
Small bowel Opacified & non-opacified
small bowel loops
CTCAE v4.0 Gr3+ 3/46
(6.5%)
No dose-volume relation-
ship found
1,7
(n/a 2–6)
2
Huang
[15]
Duodenum Duodenal bulb to ligament of
Treitz
CTCAE v4.0 Gr≥ 3 8/46
(17.4%)
With a V25 > 45% toxicity
rates increase from 8 to
48%
1,4,6,7
(n/a 2,3)
2
Kelly [13] Duodenum Gastric pylorus until end of
duodenum 3 cm past midline
CTCAE v4.0 Gr≥ 2 20/106
(18.9%)
With a V55 > 1 cc toxicity
rates increase from 9 to
47%
1,4,6,7
(n/a 2,3)
2
Verma [30] Duodenum From gastric outlet through
transverse portion of
duodenum (ascending
portion excluded)
RTOG, all grades 9 /105
(8.6%)
With a V55 > 15 cc toxicity
rates increase from 7.4 to
48.6%
1,4,6,7
(n/a 2,3)
2
Poorvu
[16]
Duodenal
segments
D1 segment: bulblike shape &
origin beyond gastric pylorus.
Transitions between 2nd &
3rd segments was lateral
border of IVC; Between 3rd &
4th was medial border of
aorta
CTCAE v4.0 Gr≥ 3 3/46
(6.5%)
No dose-volume relation-
ship found with duodenum
1,7
(n/a 2–6)
2
Abbreviations: Pts Patients, OAR Organs at risk, RT Radiotherapy, Gr Grade, CTCAE Common terminology criteria for adverse events, RTOG Radiation therapy
oncology group, LENT-SOMA Late Effects of Normal Tissue – Subjective Objective Management Analytical, RILIT Radiation induced late intestinal toxicity, EORTC
European Organisation for Research and Treatment of Cancer, Vx Volume receiving x Gy, AUC Area under curve
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Table 4 Large Bowel studies - details and quality assessment
Quality Assessment
Author OAR
studied
OAR defined Toxicity
definition
Pts with
toxicity
Significant findings Statistical
considerations
met (1–7)
Endpoint
considerations
met (1–3)
Chopra [11] Large
bowel
2 cm above target,
individual loops of large
bowel (unclear how
differentiated from small
bowel)
CTCAE v3.0
Gr ≥ 3
9/71 (12.6%) V15 associated with ≥gr 3
toxicity.
Constraints: V15 < 250 cc,
V30 < 100 cc, V40 < 90 cc to
reduce toxicity from 26.7 to
5.4%
1, 4, 6
(n/a 2,3)
2
Isohashi
[10]
Large
bowel
Single loop continuing
from end of sigmoid to
ascending colon
RTOG/EORTC,
Gr ≥ 2
16/97 (16.5%) No constraint found for large
bowel
1,7
(n/a 2–6)
2
Fonteyne
[17]
Sigmoid
colon
Where rectum sweeps
anteriorly to one slice
above aortic bifurcation
RTOG and
“RILIT” Gr 1 and
2
Gr 1112/241
(46%), Gr 2
32/241 (13%).
V40 associated with gr1
diarrhoea & blood loss.
Constraints: V40 < 10%, V30
< 16% to avoid gr1–2
diarrhoea
1, 7
(n/a 3)
1,2
Mouttet-
Audouard
[6]
Sigmoid
colon
Anterior curvature of
sigmoid colon to
anterior abdominal wall
CTCAE v4.0
Gr1–3 diarrhoea
and “whole
digestive
toxicity”
8/37 (21.6%)
diarrhoea; 17/
37
(46%) (whole
tox)
‘Whole late digestive toxicity’
associated with V30–40. No
specific constraints.
1,7
(n/a 2–6)
1,2
Lind [12] Sigmoid
colon
From where rectum
deviates from its mid-
position to where it
turns cranially in left
abdomen connecting to
colon descendens
Defecation into
clothing
without
warning > 1 in
last 6 months
63/519
(12.1%)
Mean dose>50Gy to small
bowel or sigmoid or anal
sphincter region associated
with symptom (findings for
individual organs not
clarified)
1, 7
(n/a 2–6)
1,2,3
al-Abany
[18]
Anal
sphincter
region
Caudal 3 cm of the
rectum from anal verge
(including filling)
Own
questionnaire;
Faecal leakage
>2X/week
9/65 (13.8%)
faecal leakage
Increased risk with mean
dose of 45-55Gy.
Constraints: V35 < 60%, V40
< 40% associated with no
risk of faecal leakage.
1, 7
(n/a 2,3)
1,2,3
Alsadius
[19]
Anal
sphincter
region
Caudal part of large
bowel, from end of
rectal ampulla where
bowel no longer had
visible content or air.
Own
questionnaire;
Faecal leakage
>once per
month
51/403
(12.7%) faecal
leakage
Dmean<40Gy reduces risk
from 17 to 4%.
1,2,4,7
(n/a 3)
1,2,3
Fokdal [14] Anal
canal
Outer contour of the
structure extending from
anal verge 2 cm cranially
LENT SOMA
score
Urge: 27/71
(38%);
Incontinence:
21/71 (30%)
Urgency related to Dmed>
33.8: increases toxicity 31 to
47%
Incontinence related to
Dmax> 53.8 increases 14 to
44%
1,2,4,5,7
(n/a 3)
1,2,3
Vordermark
[23]
Anal
canal
Anal verge to the
section below visible
rectal lumen,
corresponding to the
upper border of the
levator ani muscle
“Solid soiling”
(Severe
incontinence)
Own
continence
questionnaire
6/44 (14%) Severe incontinence
- associated with Dmin
(23.1Gy)
- related to portals
extending 2mm below
ischial tuberosities
(compared with 5 mm
above)
1, 7
(n/a 2–3)
1,2,3
Koper [25] Anal
canal
Caudal 3 cm of the
intestine
RTOG gr1 + 2;
Plus symptom
questionnaire.
141/248
(57%)
D90% (=54.9Gy) to
associated with ≥ gr1 rectal
toxicity
1, 7
(n/a 2–6)
2,3
Taussky [37] Anal
canal
Most distal 2-3 cm of
rectum
10 questions
from UCLA-PCI,
FACT-P &
EORTC QLQ
-PR25
Unclear no relation with anal canal
DVH found
7
(N/a: 2–3)
3
Buettner
[20]
Anal
canal
Caudal 3 cm of rectum Common
grading
57/388
(14.7%)
DSH data: Toxicity correlated
with dose to anal surface:
1,3,6,7
(n/a 2)
1,2,3
Jadon et al. Radiation Oncology           (2019) 14:57 Page 9 of 14
Table 4 Large Bowel studies - details and quality assessment (Continued)
Quality Assessment
Author OAR
studied
OAR defined Toxicity
definition
Pts with
toxicity
Significant findings Statistical
considerations
met (1–7)
Endpoint
considerations
met (1–3)
scheme;
subjective
sphincter
control at
highest grade
lateral extent 53Gy > 56%.
DVH data: Dmean 47Gy to
anal sphincter volume
correlated with sphincter
toxicity. Constraints:
Dmean<30Gy.NTCP
modeling to LKB model
TD50 = 120, m = 0.42.
Peeters [21] Anal wall Wall of caudal 3 cm of
anorectum (method
described)
RTOG/EORTC ≥
gr 2 and≥ gr 3
Plus
incontinence
pad use>2x/wk.
≥gr 2165/641
(25.7%) ≥ gr 3
27/641 4.2%
Dmean increase from 19Gy
to 52Gy increased gr2
toxicity: 16 to 31%.
V65 & Dmean most
significant for incontinence.
Dmean increase by 33Gy
increased incontinence by
12%
1,2,4,6,7
(n/a 3)
1,2
Mavroidis
[27]
Anal
sphincter
region
Musculaure layer around
the rectal aperture, 3 cm
caudal from anal verge
Own
questionnaire
faecal leakage
19/65 (29%);
blood/mucus
22/65 (34%)
Relative seriality NTCP model
of anal sphincter for
incontinence, blood/mucus.
Parameters for incontinence:
D50 = 70.2Gy, γ = 1.22, s =
0.35. Parameters for blood/
mucus: D50 = 74.0Gy, γ =
0.75, s ≈ 0
1, 3, 5, 6, 7
(n/a 2)
1,3
Peeters [28] Anal
canal wall
Wall of caudal 3 cm of
anorectum (method
described)
Incontinence
requiring pad
use>2x/wk.;
32/368 (7%) NTCP LKB model of
incontinence with anal wall
dose. Parameters found were
n = 7.48; TD50 = 105; m =
0.46
1,3,4,5,6,7
(n/a: 2)
1,3
Smeenk
[26]
Anal
sphincter
muscles
Individual muscles
defined (Internal anal
sphincter (IAS), external
anal sphincter (EAS),
puborectalis & levator
ani)
Frequency,
Urgency,
Incontinence
21/48 (44%) For complication <5%
Dmean<30Gy to IAS; <10Gy
to EAS, < 50Gy to
puborectalis, <40Gy to
levator ani
1, 4,5
(n/a 2)
1,2,3
Smeenk
[22]
Anal wall Continuation of rectal
wall from anal verge to
slice below lowest slice
with a rectal balloon
Frequency,
urgency,
incontinence
39%
frequency,
31% urgency,
31%
incontinence
For urgency:
Anal wall Dmean<38Gy risk
< 15%, >38Gy risk is 62%
1,4,7
(n/a 2,3,5,6)
1,3
Lind [12] Anal
sphincter
region
Inner muscle layer of the
sphincter up to anal
verge
Defecation into
clothing
without
warning > 1 in
last 6 months
63/519
(12.1%)
Mean dose>50Gy to small
bowel or sigmoid or anal
sphincter region associated
with this symptom
(findings for individual
organs not clarified)
1, 7 (n/a 2,3) 1,2,3
Yeoh [24] Anal wall From anorectal junction
(not clearly defined)
LENT-SOMA
total score
72% Anal wall V40 > 65%
associated with chronic
toxicity.
1,5 (n/a 2,3) 2,3
Thor [29] Anal
sphincter
Anal canal, inner and
outer sphincter (not
clearly defined)
Questionnaire
of 19 questions
in 4 domains:
pain urgency,
mucus &
incontinence.
Specific to
each of 19
question
5 LKB models proposed for
anal sphincter doses.
Low anal sphincter dose
associated with faecal
leakage and pain. High anal
sphincter dose associated
with leakage.
1,3,6 (n/a 2) 1,2,3
Ebert [35] Anal
Canal
Caudal 3 cm of
anorectum
LENT-SOMA – 8
symptoms
Specific to
each
symptom
Bleeding associated with
>40Gy, proctitis with 36-
63Gy, frequency with 8-85Gy,
urgency and tenesmus with
1,5,7 (n/a 2) 1,2,3
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[27] modelled dose to the anal sphincter region for ‘fae-
cal leakage’ and ‘blood or phlegm’ in stools using the
relative seriality NTCP model. They recommended a re-
duction in the biologically effective uniform dose (EUD)
to anal sphincter < 40–45Gy may significantly reduce
toxicity.
Quality assessment
Statistical criteria
Most studies provided information on basic statistical
data (29/30) and gave clear definitions of OARs (24/30).
Constraints were derived in 16 papers, with associated
complication rates stated in 12 papers. Goodness-of-fit
was reported in 6 studies, with discriminator statistics
reported in 10 papers. For the 4 papers with NTCP
models all provided parameter estimates with standard
error.
Endpoint criteria
Overall toxicity grades rather than individual symptoms
were assessed in 13 of 30 studies, with patient-reported
outcomes used in 14 studies (13 of which were studies
of the anal canal). 21 of the studies looked at
co-morbidity to assess its contribution to late toxicity
and this was taken into account in multivariate analyses
if thought to be associated.
Discussion
We have systematically reviewed the currently published
literature on dose-volume constraints for late bowel
toxicity after pelvic radiotherapy, excluding the rectum.
We identified 30 studies including 5136 patients. A key
finding was consistent dose-volume constraints defined
for the anal canal from five studies. For whole bowel
loops, small bowel, duodenum, large bowel and sigmoid
dose-volume constraints were derived in individual stud-
ies, however there was limited validation of these find-
ings in other studies examining the same component of
bowel.
Of all the components of bowel studied, most data
were available in the 16 studies examining the anal canal
or anal sphincter region, and these studies were most
conclusive. Statistical and endpoint measures recom-
mended by QUANTEC were met much more frequently
in these studies, data of which originated mainly from
prostate clinical trials. Fifteen of these sixteen studies
used individual symptoms reported by patients rather
than an overall toxicity score.
These studies clearly indicate a relationship between
dose-volume parameters to the anal canal and faecal in-
continence. Dmean was the most significant parameter
in five different studies, with a range of doses between
40-47Gy found. From the available data we recommend
a constraint Dmean of <40Gy (in 2Gy fractions) to the
anal canal to be included in clinical protocols in
order to limit late bowel toxicity, in particular faecal
incontinence.
For other components of bowel, the evidence was far
less conclusive, as the findings of single studies were not
corroborated with others. Possible reasons could be
Table 4 Large Bowel studies - details and quality assessment (Continued)
Quality Assessment
Author OAR
studied
OAR defined Toxicity
definition
Pts with
toxicity
Significant findings Statistical
considerations
met (1–7)
Endpoint
considerations
met (1–3)
5-34Gy to anal canal.
Abbreviations: Pts Patients, OAR Organs at risk, RT Radiotherapy, Gr Grade, CTCAE Common terminology criteria for adverse events, RTOG Radiation therapy
oncology group, LENT-SOMA Late Effects of Normal Tissue – Subjective Objective Management Analytical, RILIT Radiation induced late intestinal toxicity, EORTC
European Organisation for Research and Treatment of Cancer, Vx Volume receiving x Gy, AUC Area under curve, Dmean Mean dose, Dmax Maximal dose, DVH
Dose volume histogram, DSH Dose surface histogram, NTCP Normal Tissue Complication Probability, LKB Lyman Kutcher Burman
Table 5 Anal canal Dmean results
Study No of
pts
OAR Endpoint Dmean (in EQD2)
constraint
Risk of endpoint below this
constraint
Risk of endpoint above this
constraint
Al-albany
[18]
65 Anal sphincter
region
Incontinence >2X/week 43.2 8% 52%
Alsadius
[19]
403 Anal canal Incontinence > 1x/month 40 5.2% 21%
Buettner
[20]
388 Anal sphincter
region
Incontinence: moderate/
severe (gr2)
47, though <30Gy
ideal
5% (approx; read from
graph)
Smeenk
[22]
36 Anal canal wall Urgency present 41.8 15% 62%
Peeters
[21]
641 Anal canal wall Incontinence requiring pad
>2x/week
No constraint
specified
16% at 19Gy 31% at 52Gy
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differences in the endpoint studied (i.e toxicity, grade
and clinician versus patient-reporting) and differences in
the definition of the OARs. Furthermore different stud-
ies derive constraints with different aims, with some
using constraints to lower the risk of toxicity to a certain
level eg. to 5% or to 20%, and others attempt to derive
constraints with the aim of no toxicity at all.
For example when considering constraints for bowel
loops, both Guerrero-Urbano et al. [8] and McDonald et
al. [9] derived constraints for V40, V45 and V60 associated
with late bowel toxicity. However, the constraints in these
studies differed, with one suggesting V40 < 124 cc, V45 <
71 cc and V60 < 0.5 cc, and the other recommending V40
< 151 cc, V45 < 139 cc and V60 < 98 cc, despite the same
definition of bowel loops, and use of RTOG scoring. Rea-
sons for these differences could be due to differences in
endpoint definition, with one study looking specifically at
≥ grade 2 RTOG diarrhoea, with the other looking at over-
all RTOG toxicity ≥ grade 1. McDonald et al. determined
constraints aiming to reduce the risk of ≥grade 1 toxicity
specifically to less than 25%, whereas Guerrero-Urbano et
al. found constraints with the aim of reducing ≥grade 2
toxicity, but the level to which this aims to reduce the risk
of toxicity is unclear.
A similar lack of consistency was seen for studies fo-
cussed on duodenum [13, 30], large bowel [10] and sig-
moid colon [6, 17] making it difficult to further
recommend constraints for these OARs. Future valid-
ation of the published constraints using independent
data sets from patients using the same toxicity end-
points, same OAR definitions and the same aim in terms
of toxicity reduction, would be a useful next step to im-
prove knowledge on this subject.
Many studies found no correlation with OAR dose pa-
rameters and late bowel toxicity at all. This lack of find-
ings could be due to a variety of methodological reasons
– many of the studies were underpowered with only a
very small incidence of the defined toxicity, making it
difficult to determine the likely predictors of these toxic-
ities in only a handful of patients. Many studies have not
collected baseline data and presume the presence of
bowel symptoms post-radiotherapy is treatment related,
when in fact these symptoms may have been
pre-existing, or due to a separate bowel pathology. Fur-
ther a known issue within the pelvis, is that of organ
motion of bowel and its subsection, and the use of a sin-
gle CT scan to define a highly mobile structure may not
be an appropriate approach.
Aside from methodology the reason for lack of positive
findings may be in fact that particular OARs may genu-
inely not have any influence on late toxicity, and rather
than dose-volume predictors, other considerations such
as inherent radiosensitivity of individual patients, may be
the main predictors of toxicity.
For acute bowel toxicity QUANTEC have suggested
two constraints: V45 < 195 cc for peritoneal cavity, and
V15 < 120 cc for small bowel loops. The QUANTEC au-
thors suggest these constraints may be applicable for late
bowel toxicity. Some consistency is seen to QUANTEC
recommendations within this review with Chopra et al.
[11] finding V15 small bowel loops to be important on
multivariate analysis, although their recommended con-
straint was much higher at V15 < 275 cc.
For peritoneal cavity, the findings of the studies
reviewed do not corroborate with QUANTEC. Three
studies found no correlation of peritoneal cavity doses
with late toxicity, and the two positive studies found that
in fact lower doses to peritoneal cavity of V20 and V10–
30 [6, 31] were predictive of late toxicity. It would be im-
portant to validate the significance of these low doses in
terms of late toxicity given the increased use of volumet-
ric arc therapy (VMAT) techniques in recent years,
where lower dose bath to a larger area of normal tissue
is seen, the significance of which is currently not
understood.
Strengths of this systematic review are the broad inclu-
sivity of the search, with the studies included having pa-
tients with different tumour types, radiotherapy
techniques, fractionations, and concurrent treatments. A
similar approach was used in key papers such as the
Emami et al. data [32], as well as the QUANTEC papers
[3, 4], where bowel constraints were sought from studies
with gynaecological, rectal, prostate and pancreatic can-
cers. A potential limitation of this is that some of these
treatment factors may influence late toxcity (e.g. use of
concurrent systemic agents, or hypofractionation). Al-
though it is expected that individual authors may ac-
count for these factors statistically this may not have
always been done and may explain partly the inconsist-
ent results found.
Despite attempting to be as inclusive as possible we may
have missed those studies not in English, and from grey
literature currently unpublished. Studies involving SBRT
were excluded given the questionable validity of the linear
quadratic model with extreme hypofractionation thus
making radiobiological comparisons difficult [33].
Quality assessment based on the QUANTEC-defined
criteria added much value to this review, highlighting
that many researchers do not report or consider the
endpoint or statistical criteria, and further that those
that do adhere to these criteria appear to have more
conclusive findings.
Conclusions
We recommend the use of Dmean to the anal canal of
<40Gy in pelvic radiotherapy protocols as a constraint to
reduce the development of late bowel toxicity, in par-
ticular faecal incontinence.
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Other important organs at risk to consider are whole
bowel loops, small bowel, duodenum, large bowel and
sigmoid colon and constraints for these OARS are noted
in this review. However, clear recommendations for
these organs cannot be made, due to lack of correlation
between studies. Validation of the constraints found
within this systematic review for these OARS with inde-
pendent data sets would be an important next step. If
validated these constraints could be used clinically in
prospective patients, and also as a relevant benchmark
to assess the likely impact of advanced radiotherapy
techniques on late toxicity. Future studies should con-
sider the quality criteria recommended by QUANTEC.
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